$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
What is the cure rate for NTRK gene fusion with larotrectinib/vitaca?
2026-02-01 22:25:32
Check Details
How long is the validity period of Selinexol/Silvio tablets?
2026-02-01 22:25:32
Check Details
The therapeutic effect and real feedback of Avonib (Tosuvo) on leukemia patients
2026-02-01 22:25:32
Check Details
Can I stop taking Mitotane once I start taking it?
2026-02-01 22:25:32
Check Details
Analysis of the differences between pemetinib (Dabotan) and first-, second- and third-generation targeted drugs
2026-02-01 22:25:32
Check Details
Erdafitinib (Boke) belongs to which generation of targeted drugs and its differences from similar drugs
2026-02-01 22:25:32
Check Details
When was Erlotinib officially launched in China and its post-marketing applications?
2026-02-01 22:25:32
Check Details
Can tofacitinib (Shangjie) be taken for a long time and recommendations for safe use by patients with chronic diseases
2026-02-01 22:25:32
Check Details
Discussion on whether taking cycloserine for three months will increase the risk of leukemia
2026-02-01 22:25:32
Check Details
What kind of important antibacterial drugs does linezolid (Siwo) belong to and its hierarchical management status?
2026-02-01 22:25:32
Check Details
Patients’ personal experiences after taking Ribociclib (Kaillon) for one year, including efficacy stability and side effects
2026-02-01 22:25:32
Check Details
Analysis of which immune antibody type Cemiplimab, as a PD-1 antibody drug, belongs to
2026-02-01 22:25:32
Check Details
1
2
...
2431
2432
2433
2434
2435
2436
2437
2438
2439
2440
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
ROS and Cancer: The Potential of Natural Antioxidants
2
SKYSCRAPER-02C Study: New Hope for Extensive-Stage Small Cell Lung Cancer Treatment
3
LPCAT3: The Key Player in MASH Progression to Hepatocellular Carcinoma
4
Breztri Aerosphere Approved by US FDA for Maintenance Treatment of Asthma in Patients Aged 12 Years and Older
5
Datopotamab Deruxtecan as First-Line Treatment for Advanced Triple-Negative Breast Cancer: Full Interpretation of the Phase III TROPION-Breast02 Trial
6
Olaparib Plus Pembrolizumab Maintenance Therapy for Metastatic Pancreatic Cancer: Findings from the POLAR Phase II Basket Trial
7
From Causes to Treatments—Exploring Medical Breakthroughs
8
IRX4 Transcription Factor: New Research Insights on Colorectal Cancer Treatment Targets
9
New Research Progress on Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Tumor Relationship
10
Tyrosine Kinase and JAK Inhibitors May Increase Keratinocyte Carcinoma Risk: New Research Reveals Drug Safety Findings
11
CLISGen Database: A New Tool for Cell Line Selection in Cancer Genetic Variation Research
12
RAS Targeted Therapy Resistance Breakthrough: mTORC1 is Key, Dalifarnib Combination Therapy Brings Hope